^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Graspa (eryaspase)

    i
    Other names: ERY001, ERY-001, ERY-ASP
    Company:
    PHAXIAM Therap
    Drug class:
    Asparagine depleter
    Related drugs:
    1year
    Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Georgetown University | Trial completion date: Dec 2023 --> Jul 2024
    Trial completion date • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Graspa (eryaspase)
    over1year
    Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Georgetown University | Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2022
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Graspa (eryaspase)
    over2years
    Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) (clinicaltrials.gov)
    P2/3, N=27, Terminated, ERYtech Pharma | N=64 --> 27 | Recruiting --> Terminated; sponsor decision
    Enrollment change • Trial termination • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification
    |
    carboplatin • gemcitabine • Graspa (eryaspase)
    3years
    Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2) (clinicaltrials.gov)
    P2/3, N=64, Recruiting, ERYtech Pharma | Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Dec 2020 --> Feb 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification
    |
    carboplatin • gemcitabine • Graspa (eryaspase)
    almost4years
    Trybeca-1: Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (clinicaltrials.gov)
    P3, N=500, Active, not recruiting, ERYtech Pharma | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2020 --> Aug 2021
    Clinical • Enrollment closed • Trial primary completion date • Combination therapy
    |
    ALB (Albumin)
    |
    gemcitabine • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Graspa (eryaspase) • fluorouracil topical
    almost5years
    Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2) (clinicaltrials.gov)
    P2/3, N=64, Recruiting, ERYtech Pharma | Not yet recruiting --> Recruiting | Trial completion date: Apr 2020 --> Dec 2020 | Trial primary completion date: Apr 2020 --> Dec 2020
    Clinical • Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 amplification
    |
    carboplatin • gemcitabine • Graspa (eryaspase)